

(e) the amino acid sequence of a sequence variant of the amino acid sequence shown in SEQ ID NO:1, wherein the sequence variant is encoded by a nucleic acid molecule that hybridizes to the nucleotide sequence shown in SEQ ID NO:2 under stringent conditions;

(f) the amino acid sequence of a sequence variant of the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Patent Deposit No. \_\_\_\_, wherein the sequence variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the cDNA insert of the plasmid deposited with ATCC as Patent Deposit No. \_\_\_\_;

(g) The amino acid sequence of the mature receptor polypeptide set forth as amino acid 6 to amino acid 370 of SEQ ID NO:1; and

(h) The amino acid sequence from amino acid 6 to amino acid 370 of the polypeptide encoded by the cDNA clone contained in ATCC Deposit No. \_\_\_\_;

the method comprising contacting the polypeptide with an agent under conditions that allow the agent to modulate the activity of the polypeptide, wherein said modulation is in cells derived from tissues selected from the group consisting of brain, spleen, lung, kidney, skeletal muscle, liver, and heart.

21. The method of claim 19/20], wherein said cells are brain cells.

Please add new claims 23-31:

23. The method of claim 19, wherein said activity is G-protein coupled receptor activity.

24. The method of claim 23, wherein said activity is a signaling activity or cellular

response.

25. A method for identifying a compound that modulates the activity of a polypeptide comprising an amino acid selected from the group consisting of:

- (a) the amino acid sequence shown in SEQ ID NO:1;
- (b) the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Patent Deposit No. \_\_\_\_\_;
- (c) the amino acid sequence of an allelic variant of the amino acid sequence shown in SEQ ID NO:1;
- (d) the amino acid sequence of an allelic variant of the amino acid sequence encoded by the cDNA of the plasmid deposited with ATCC as Patent Deposit No. \_\_\_\_\_;
- (e) the amino acid sequence of a sequence variant of the amino acid sequence shown in SEQ ID NO:1, wherein the sequence variant is encoded by a nucleic acid molecule that hybridizes to the nucleotide sequence shown in SEQ ID NO:2 under stringent conditions;
- (f) the amino acid sequence of a sequence variant of the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Patent Deposit No. \_\_\_\_\_, wherein the sequence variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the cDNA insert of the plasmid deposited with ATCC as Patent Deposit No. \_\_\_\_\_;
- (g) The amino acid sequence of the mature receptor polypeptide set forth as amino acid 6 to amino acid 370 of SEQ ID NO:1; and
- (h) The amino acid sequence from amino acid 6 to amino acid 370 of the polypeptide encoded by the cDNA clone contained in ATCC Deposit No. \_\_\_\_\_;

the method comprising contacting a cell expressing the polypeptide with a test compound under conditions such that the test compound can modulate the activity of the polypeptide and assessing the activity of the polypeptide to thereby determine if the test compound is a compound

In re: Glucksmann *et al.*  
Appl. No.: 09/383,745  
Filed: August 26, 1999  
Page 4 of 8

---

that modulates the activity of the polypeptide, wherein the cell is derived from a tissue selected from the group consisting of: brain, spleen, lung, kidney, skeletal muscle, liver, and heart.

26. The method of claim 25, wherein said activity is G-protein coupled receptor activity.

27. The method of claim 26, wherein said activity is a signaling activity or cellular response.

28. A method for identifying a compound that inhibits the binding of an agent to a polypeptide comprising an amino acid selected from the group consisting of:

- (a) the amino acid sequence shown in SEQ ID NO:1;
- (b) the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Patent Deposit No. \_\_\_\_\_;
- (c) the amino acid sequence of an allelic variant of the amino acid sequence shown in SEQ ID NO:1;
- (d) the amino acid sequence of an allelic variant of the amino acid sequence encoded by the cDNA of the plasmid deposited with ATCC as Patent Deposit No. \_\_\_\_\_;
- (e) the amino acid sequence of a sequence variant of the amino acid sequence shown in SEQ ID NO:1, wherein the sequence variant is encoded by a nucleic acid molecule that hybridizes to the nucleotide sequence shown in SEQ ID NO:2 under stringent conditions;
- (f) the amino acid sequence of a sequence variant of the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Patent Deposit No. \_\_\_\_\_, wherein the sequence variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the cDNA insert of the plasmid deposited with ATCC as Patent Deposit No. \_\_\_\_\_;